Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756578 | 1.00 | EGFR (0.51) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6756576 | 1.00 | EGFR (0.51) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6756742 | 0.84 | RAB9A (0.66) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6756745 | 0.84 | RAB9A (0.66) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6756739 | 0.84 | RAB9A (0.66) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6759878 | 0.82 | EGFR (0.50) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6755624 | 0.79 | MAOB (0.65) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6755622 | 0.79 | MAOB (0.65) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6755620 | 0.79 | MAOB (0.65) | EGFRMAOBMAPTRAB9ANPC1 | |
| SCHEMBL6754286 | 0.75 | EGFR (0.49) | EGFRMAOBMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | EGFR 1431/4885MAOB 1077/4885MAPT 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.